Drug repurposing strategies and key challenges for COVID-19 management

References

• Jawed A, Parveen R, Dar S, et al. Repurposed drugs as a ray of hope for COVID-19 patients. Acta Sci Microbiol. 2021;4(5):23–27.
   Google Scholar
• Zhou P, Yang X-L, Wang X-G, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. BioRxiv; 2020.
   Google Scholar
• Agrawal M, Saraf S, Saraf S, et al. In-line treatments and clinical initiatives to fight against COVID-19 outbreak. Respir Med. 2020;106192.
   Google Scholar
• Shirbhate E, Pandey J, Patel VK, et al. Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention. Pharmacol Rep. 2021;73(6):1539–1550.
   PubMed Web of Science ®Google Scholar
• Gorain B, Choudhury H, Molugulu N, et al. Fighting strategies against the novel coronavirus pandemic: impact on global economy, front. Public Health. 2020;8:800.
   Web of Science ®Google Scholar
• Singh S, Numan A, Sharma D, et al. Epidemiology, virology and clinical aspects of hantavirus infections: an overview. Int J Environ Health Res. 2021;1–13.
   Google Scholar
• Huang F, Zhang C, Liu Q, et al. Identification of amitriptyline HCl, flavin adenine dinucleotide, azacitidine and calcitriol as repurposing drugs for influenza a H5N1 virus-induced lung injury. PLoS Pathog. 2020;16(3):e1008341.
   PubMed Web of Science ®Google Scholar
• Scherman D, Fetro C. Drug repositioning for rare diseases: knowledge-based success stories. Therapies. 2020;75(2):161–167.
   PubMed Web of Science ®Google Scholar
• Paolini GV, Shapland RHB, van Hoorn WP, et al. Global mapping of pharmacological space. Nat Biotechnol. 2006;24(7):805–815.
   PubMed Web of Science ®Google Scholar
• Malani M, Salunke P, Kulkarni S, et al. Repurposing pharmaceutical excipients as an antiviral agent against SARS-CoV-2. J Biomater Sci Polym Ed. 2021;1–27.
   Google Scholar
• Hodos RA, Kidd BA, Shameer K, et al. In silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med. 2016;8(3):186–210.
   PubMed Web of Science ®Google Scholar
• Piro RM. Network medicine: linking disorders. Hum Genet. 2012;131(12):1811–1820.
   PubMed Web of Science ®Google Scholar
• Ng YL, Salim CK, Chu JJH. Drug repurposing for COVID-19: approaches, challenges and promising candidates. Pharmacol Ther. 2021;228:107930.
   PubMed Web of Science ®Google Scholar
• Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23.
   PubMedGoogle Scholar
• Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538):eabg3055.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Hofmann-Winkler H, Krüger N, et al. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep. 2021;36(3):109415.
   PubMed Web of Science ®Google Scholar
• Gan HH, Twaddle A, Marchand B, et al. Structural modeling of the SARS-CoV-2 spike/human ACE2 complex interface can identify high-affinity variants associated with increased transmissibility. J Mol Biol. 2021;433(15):167051.
   PubMed Web of Science ®Google Scholar
• Chang C, Lo S-C, Wang Y-S, et al. Recent insights into the development of therapeutics against coronavirus diseases by targeting N protein. Drug Discov Today. 2016;21(4):562–572.
   PubMed Web of Science ®Google Scholar
• Chang C, Sue S-C, Yu T, et al. Modular organization of SARS coronavirus nucleocapsid protein. J Biomed Sci. 2006;13(1):59–72.
   PubMed Web of Science ®Google Scholar
• Yu I-M, Oldham ML, Zhang J, et al. Crystal structure of the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein dimerization domain reveals evolutionary linkage between corona- and arteriviridae. J Biol Chem. 2006;281(25):17134–17139.
   PubMed Web of Science ®Google Scholar
• Wang YS, Chang CK, Hou MH. Crystallographic analysis of the N-terminal domain of Middle East respiratory syndrome coronavirus nucleocapsid protein. Acta Crystallogr F Struct Biol Commun. 2015;71(Pt 8):977–980.
   PubMedGoogle Scholar
• Kang S, Yang M, Hong Z, et al. Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm Sin B. 2020;10(7):1228–1238.
   PubMed Web of Science ®Google Scholar
• Lin S-M, Lin S-C, Hsu J-N, et al. Structure-based stabilization of non-native protein–protein interactions of coronavirus nucleocapsid proteins in antiviral drug design. J Med Chem. 2020;63(6):3131–3141.
   PubMed Web of Science ®Google Scholar
• Walls AC, Park Y-J, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281–292.e6.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 2015;116:76–84.
   Google Scholar
• Wang K, Chen W, Zhou Y-S, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. BioRxiv; 2020.
   Google Scholar
• Zhang L, Lin D, Sun X, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020;368(6489):409–412.
   PubMed Web of Science ®Google Scholar
• Lee H, Cao S, Hevener KE, et al. Synergistic inhibitor binding to the papain-like protease of human SARS coronavirus: mechanistic and inhibitor design implications. ChemMedChem. 2013;8(8):1361–1372.
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Brindisi M, Shahabi D, et al. Drug development and medicinal chemistry efforts toward SARS-coronavirus and covid-19 therapeutics. ChemMedChem. 2020;15(11):907–932.
   PubMed Web of Science ®Google Scholar
• Morse JS, Lalonde T, Xu S, et al. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem. 2020;21(5):730–738.
   PubMed Web of Science ®Google Scholar
• Jin Z, Du X, Xu Y, et al. Structure of mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582(7811):289–293.
   PubMed Web of Science ®Google Scholar
• Nutho B, Mahalapbutr P, Hengphasatporn K, et al. Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms. Biochemistry. 2020;59(18):1769–1779.
   PubMed Web of Science ®Google Scholar
• McDonald SM. RNA synthetic mechanisms employed by diverse families of RNA viruses. Wiley Interdiscip Rev RNA. 2013;4(4):351–367.
   PubMed Web of Science ®Google Scholar
• De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29(3):695–747.
   PubMed Web of Science ®Google Scholar
• Gao Y, Yan L, Huang Y, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020;368(6492):779–782.
   PubMed Web of Science ®Google Scholar
• Chan JF-W, Kok K-H, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–236.
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653.
   PubMed Web of Science ®Google Scholar
• Jia Z, Yan L, Ren Z, et al. Delicate structural coordination of the severe acute respiratory syndrome coronavirus Nsp13 upon ATP hydrolysis. Nucleic Acids Res. 2019;47(12):6538–6550.
   PubMed Web of Science ®Google Scholar
• Ng ML, Tan SH, See EE, et al. Early events of SARS coronavirus infection in vero cells. J Med Virol. 2003;71(3):323–331.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.
   PubMed Web of Science ®Google Scholar
• Zhang H, Penninger JM, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–590.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li L. SARS-CoV-2: virus dynamics and host response. Lancet Infect Dis. 2020;20(5):515–516.
   PubMed Web of Science ®Google Scholar
• Kumar P, Sah AK, Tripathi G, et al. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19. Mol Cell Biochem. 2021;476(2):553–574.
   PubMed Web of Science ®Google Scholar
• Wösten-van Asperen RM, Lutter R, Specht PA, et al. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. J Pathol. 2011;225(4):618–627.
   PubMed Web of Science ®Google Scholar
• Haschke M, Schuster M, Poglitsch M, et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet. 2013;52(9):783–792.
   PubMed Web of Science ®Google Scholar
• Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905–913.e7.
   PubMed Web of Science ®Google Scholar
• Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A. 2020;117(13):7001–7003.
   PubMed Web of Science ®Google Scholar
• Vaarala MH, Porvari KS, Kellokumpu S, et al. Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues. J Pathol. 2001;193(1):134–140.
   PubMed Web of Science ®Google Scholar
• Zumla A, Chan JFW, Azhar EI, et al. Coronaviruses – drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327–347.
   PubMed Web of Science ®Google Scholar
• Shen LW, Mao HJ, Wu YL, et al. TMPRSS2: a potential target for treatment of influenza virus and coronavirus infections. Biochimie. 2017;142:1–10.
   PubMed Web of Science ®Google Scholar
• Maggio R, Corsini GU. Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection. Pharmacol Res. 2020;157:104837.
   PubMed Web of Science ®Google Scholar
• Wang X, Dhindsa R, Povysil G, et al. Transcriptional inhibition of host viral entry proteins as a therapeutic strategy for SARS-CoV-2; 2020.
   Google Scholar
• Stopsack KH, Mucci LA, Antonarakis ES, et al. TMPRSS2 and COVID-19: serendipity or opportunity for intervention? Cancer Discov. 2020;10(6):779–782.
   PubMed Web of Science ®Google Scholar
• Jin X, Xu K, Jiang P, et al. Virus strain from a mild COVID-19 patient in Hangzhou represents a new trend in SARS-CoV-2 evolution potentially related to furin cleavage site. Emerg Microbes Infect. 2020;9(1):1474–1488.
   PubMed Web of Science ®Google Scholar
• Hasan A, Paray BA, Hussain A, et al. A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin. J Biomol Struct Dyn. 2021;39(8):3025–3033.
   PubMed Web of Science ®Google Scholar
• Usul Afsar C. 2019-nCoV-SARS-CoV-2 (COVID-19) infection: cruciality of furin and relevance with cancer. Med Hypotheses. 2020;140:109770.
   PubMed Web of Science ®Google Scholar
• Ivanova T, Hardes K, Kallis S, et al. Optimization of substrate-analogue furin inhibitors. ChemMedChem. 2017;12(23):1953–1968.
   PubMed Web of Science ®Google Scholar
• Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1620.
   PubMed Web of Science ®Google Scholar
• Liu S, Xiao G, Chen Y, et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet. 2004;363(9413):938–947.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 2020;78(4):779–784.e5.
   PubMed Web of Science ®Google Scholar
• Yuan L, Zou C, Ge W, et al. A novel cathepsin L inhibitor prevents the progression of idiopathic pulmonary fibrosis. Bioorg Chem. 2020;94:103417.
   PubMed Web of Science ®Google Scholar
• Padmanabhan P, Desikan R, Dixit N. Targeting TMPRSS2 and cathepsin B/L together may be synergistic against SARS-CoV-2 infection. PLoS Comput Biol. 2020;16(12):e1008461.
   PubMed Web of Science ®Google Scholar
• Bekerman E, Neveu G, Shulla A, et al. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest. 2017;127(4):1338–1352.
   PubMed Web of Science ®Google Scholar
• Verdonck S, Pu S-Y, Sorrell FJ, et al. Synthesis and structure–activity relationships of 3,5-disubstituted-pyrrolo[2,3-b]pyridines as inhibitors of adaptor-associated kinase 1 with antiviral activity. J Med Chem. 2019;62(12):5810–5831.
   PubMed Web of Science ®Google Scholar
• Pu S-Y, Xiao F, Schor S, et al. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. Antiviral Res. 2018;155:67–75.
   PubMed Web of Science ®Google Scholar
• Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–e31.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–402.
   PubMed Web of Science ®Google Scholar
• Praveen D, Puvvada RC, Vijey Aanandhi M. Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19. Int J Antimicrob Agents. 2020;55(5):105967.
   PubMed Web of Science ®Google Scholar
• Shisheva A. PIKfyve: partners, significance, debates and paradoxes. Cell Biol Int. 2008;32(6):591–604.
   PubMed Web of Science ®Google Scholar
• He K, Marsland R III, Upadhyayula S, et al. Dynamics of phosphoinositide conversion in clathrin-mediated endocytic traffic. Nature. 2017;552(7685):410–414.
   PubMed Web of Science ®Google Scholar
• de Lartigue J, Polson H, Feldman M, et al. PIKfyve regulation of endosome-linked pathways. Traffic. 2009;10(7):883–893.
   PubMed Web of Science ®Google Scholar
• Ikonomov OC, Sbrissa D, Shisheva A. YM201636, an inhibitor of retroviral budding and PIKfyve-catalyzed PtdIns(3,5)P2 synthesis, halts glucose entry by insulin in adipocytes. Biochem Biophys Res Commun. 2009;382(3):566–570.
   PubMed Web of Science ®Google Scholar
• Wada Y, Cardinale I, Khatcherian A, et al. Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis. PLOS One. 2012;7(4):e35069.
   PubMed Web of Science ®Google Scholar
• Grimm C, Chen C-C, Wahl-Schott C, et al. Two-pore channels: catalyzers of endolysosomal transport and function. Front Pharmacol. 2017;8:45.
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Kolokoltsov AA, Chen C-C, et al. Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. Science. 2015;347(6225):995–998.
   PubMed Web of Science ®Google Scholar
• Penny CJ, Vassileva K, Jha A, et al. Mining of Ebola virus entry inhibitors identifies approved drugs as two-pore channel pore blockers. Biochim Biophys Acta Mol Cell Res. 2019;1866(7):1151–1161.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wong R, Soo YOY, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44–46.
   PubMed Web of Science ®Google Scholar
• Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in covid-19: possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554.
   PubMed Web of Science ®Google Scholar
• Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. Early convalescent plasma for high-risk outpatients with Covid-19. N Engl J Med. 2021.
   Google Scholar
• Mullard A. Parsing clinical success rates. Nat Rev Drug Discov. 2016;15(7):447.
   Web of Science ®Google Scholar
• Dowden H, Munro J. Trends in clinical success rates and therapeutic focus. Nat Rev Drug Discov. 2019;18(7):495–496.
   PubMed Web of Science ®Google Scholar
• Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58.
   PubMed Web of Science ®Google Scholar
• Pillaiyar T, Meenakshisundaram S, Manickam M, et al. A medicinal chemistry perspective of drug repositioning: recent advances and challenges in drug discovery. Eur J Med Chem. 2020;195:112275.
   PubMed Web of Science ®Google Scholar
• Guy RK, DiPaola RS, Romanelli F, et al. Rapid repurposing of drugs for COVID-19. Science. 2020;368(6493):829–830.
   PubMed Web of Science ®Google Scholar
• Wang J. Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. J Chem Inf Model. 2020;60(6):3277–3286.
   PubMed Web of Science ®Google Scholar
• Wang X, Guan Y. COVID-19 drug repurposing: a review of computational screening methods, clinical trials, and protein interaction assays. Med Res Rev. 2021;41(1):5–28.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang F, Tang J, et al. Artificial intelligence in COVID-19 drug repurposing. Lancet Digit Health. 2020;2(12):e667–e676.
   PubMedGoogle Scholar
• Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
   PubMed Web of Science ®Google Scholar
• Riva L, Yuan S, Yin X, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586(7827):113–119.
   PubMed Web of Science ®Google Scholar
• Singh TU, Parida S, Lingaraju MC, et al. Drug repurposing approach to fight COVID-19. Pharmacol Rep. 2020;72(6):1479–1508.
   PubMed Web of Science ®Google Scholar
• Chiquete E, Alegre-Díaz J, Ochoa-Guzmán A, et al. Ethnicity and other COVID-19 death risk factors in Mexico. Arch Med Sci. 2020.
   Google Scholar
• Douangamath A, Fearon D, Gehrtz P, et al. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nat Commun. 2020;11(1):5047.
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe covid-19. N Engl J Med. 2020;382(19):1787–1799.
   PubMed Web of Science ®Google Scholar
• Sisay M. 3CLpro inhibitors as a potential therapeutic option for COVID-19: available evidence and ongoing clinical trials. Pharmacol Res. 2020;156:104779.
   PubMed Web of Science ®Google Scholar
• Horby PW, Mafham M, Bell JL, et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345–1352.
   PubMed Web of Science ®Google Scholar
• Ahmad J, Ikram S, Ahmad F, et al. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) – a drug repurposing study. Heliyon. 2020;6(7):e04502.
   PubMed Web of Science ®Google Scholar
• Pan H, Peto R, Henao-Restrepo A-M, et al. Repurposed antiviral drugs for covid-19 - Interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497–511.
   PubMed Web of Science ®Google Scholar
• Dragoni F, Boccuto A, Picarazzi F, et al. Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro. Antiviral Res. 2020;175:104708.
   PubMed Web of Science ®Google Scholar
• Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459–468.
   PubMed Web of Science ®Google Scholar
• Hillen HS, Kokic G, Farnung L, et al. Structure of replicating SARS-CoV-2 polymerase. Nature. 2020;584(7819):154–156.
   PubMed Web of Science ®Google Scholar
• Zhu W, Chen CZ, Gorshkov K, et al. RNA-dependent RNA polymerase as a target for COVID-19 drug discovery. SLAS Discov. 2020;25(10):1141–1151.
   PubMed Web of Science ®Google Scholar
• Shukla R, Aparnasai RG, Handa M. Convalescent plasma for treatment of COVID-19 infection. In: Anoop Kumar, editor. COVID-19: current challenges and future perspectives. Singapore: Bentham Science Publishers; 2021. p. 43.
   Google Scholar
• Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100(2):446–454.
   PubMed Web of Science ®Google Scholar
• Tahara J, Uehara T, Sakao S, et al. A case report of COVID-19 pneumonia including use of favipiravir. Japan Med J. 2020;5012:1–2.
   Google Scholar
• Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020;6(10):1192–1198.
   Web of Science ®Google Scholar
• Chen C, Zhang Y, Huang J, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial; 2020.
   Google Scholar
• Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381–385.
   PubMed Web of Science ®Google Scholar
• Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9(2):e00221-18.
   PubMed Web of Science ®Google Scholar
• Pardo J, Shukla AM, Chamarthi G, et al. The journey of remdesivir: from Ebola to COVID-19. Drugs Context. 2020;9:1–9.
   Google Scholar
• Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295(20):6785–6797.
   PubMed Web of Science ®Google Scholar
• Eastman RT, Roth JS, Brimacombe KR, et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci. 2020;6(5):672–683.
   PubMed Web of Science ®Google Scholar
• WHO’s response to Covid-19; 2021.
   Google Scholar
• Burki TK. Completion of clinical trials in light of COVID-19. Lancet Respir Med. 2020;8(12):1178–1180.
   PubMed Web of Science ®Google Scholar
• Humeniuk R, Mathias A, Cao H, et al. Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects. Clin Transl Sci. 2020;2019:896–906.
   Google Scholar
• Elsawah HK, Elsokary MA, Abdallah MS, et al. Efficacy and safety of remdesivir in hospitalized covid-19 patients: systematic review and meta-analysis including network meta-analysis. Rev Med Virol. 2021;31(4):e2187.
   PubMed Web of Science ®Google Scholar
• Zampino R, Mele F, Florio LL, et al. Liver injury in remdesivir-treated COVID-19 patients. Hepatol Int. 2020;14(5):881–883.
   PubMed Web of Science ®Google Scholar
• Montastruc F, Thuriot S, Durrieu G. Hepatic disorders with the use of remdesivir for coronavirus 2019. Clin Gastroenterol Hepatol. 2020;18(12):2835–2836.
   PubMed Web of Science ®Google Scholar
• Tang X, Ye X, Ye Y, et al. Remdesivir in adults with severe COVID-19: a randomised. Lancet. 2020;395(10236):1569–1578.
   PubMed Web of Science ®Google Scholar
• Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe covid-19. N Engl J Med. 2020;382(24):2327–2336.
   PubMed Web of Science ®Google Scholar
• Huang X, Xu Y, Yang Q, et al. Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials. Sci Rep. 2015;5:8528.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Girard P-M, Landman R, et al. Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015;15(7):785–792.
   PubMed Web of Science ®Google Scholar
• Rispetto S. Lopinavir/ritonavir. 2020;2020:17–20.
   Google Scholar
• Owa AB, Owa OT. Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial? J Microbiol Immunol Infect. 2020;53(5):674–5.
   Google Scholar
• Giacomelli A, Pagani G, Ridolfo AL, et al. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study. J Med Virol. 2021;93(3):1421–1427.
   PubMed Web of Science ®Google Scholar
• Meini S, Pagotto A, Longo B, et al. Role of lopinavir/ritonavir in the treatment of covid-19: a review of current evidence, guideline recommendations, and perspectives. J Clin Med. 2020;9(7):2050.
   Web of Science ®Google Scholar
• Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, et al. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther. 2014;143(2):225–245.
   PubMed Web of Science ®Google Scholar
• Zimmermann P, Ziesenitz VC, Curtis N, et al. The immunomodulatory effects of macrolides—a systematic review of the underlying mechanisms. Front Immunol. 2018;9:302.
   PubMed Web of Science ®Google Scholar
• Arabi YM, Deeb AM, Al-Hameed F, et al. Macrolides in critically ill patients with Middle East respiratory syndrome. Int J Infect Dis. 2019;81:184–190.
   PubMed Web of Science ®Google Scholar
• Molina JM, Delaugerre C, Goff JL, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50(4):384.
   PubMed Web of Science ®Google Scholar
• Chorin E, Wadhwani L, Magnani S, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm. 2020;17(9):1425–1433.
   PubMed Web of Science ®Google Scholar
• Chorin E, Dai M, Shulman E, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med. 2020;26(6):808–809.
   PubMed Web of Science ®Google Scholar
• Furtado RHM, Berwanger O, Fonseca HA, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396(10256):959–967.
   PubMed Web of Science ®Google Scholar
• Baron SA, Devaux C, Colson P, et al. Teicoplanin: an alternative drug for the treatment of COVID-19? Int J Antimicrob Agents. 2020;55(4):105944.
   PubMed Web of Science ®Google Scholar
• Solomon VR, Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol. 2009;625(1–3):220–233.
   PubMed Web of Science ®Google Scholar
• Dwivedi P, Khatik R, Khandelwal K, et al. Preparation and characterization of solid lipid nanoparticles of antimalarial drug arteether for oral administration. J Biomater Tissue Eng. 2014.
   Google Scholar
• Yan Y, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza a H5N1 virus infection in an animal model. Cell Res. 2013;23(2):300–302.
   PubMed Web of Science ®Google Scholar
• Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6(1):16.
   PubMed Web of Science ®Google Scholar
• Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722–727.
   PubMed Web of Science ®Google Scholar
• Fantini J, Scala CD, Chahinian H, et al. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 2020;55(5):105960.
   PubMed Web of Science ®Google Scholar
• Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. COVID-19: reminder of the risks of chloroquine and hydroxychloroquine. Vol. 31; 2020. p. 8–11.
   Google Scholar
• FDA. FDA drug safety communication. Safety announcement [cited 2020 Apr 24]; 2020.
   Google Scholar
• Momekov G, Momekova D. Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. Biotechnol Biotechnol Equip. 2020;34(1):469–474.
   Web of Science ®Google Scholar
• Lokhande AS, Devarajan PV. A review on possible mechanistic insights of nitazoxanide for repurposing in COVID-19. Eur J Pharmacol. 2021;891:173748.
   PubMed Web of Science ®Google Scholar
• Pindiprolu SKSS, Pindiprolu SH. Plausible mechanisms of niclosamide as an antiviral agent against COVID-19. Med Hypotheses. 2020;140:109765.
   PubMed Web of Science ®Google Scholar
• Abeygunasekera A, Jayasinghe S. Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19? Med Hypotheses. 2020;143:109843.
   PubMed Web of Science ®Google Scholar
• Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117:10970–10975.
   PubMed Web of Science ®Google Scholar
• Sallard E, Lescure F-X, Yazdanpanah Y, et al. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020;178:104791.
   PubMed Web of Science ®Google Scholar
• Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323:1824–1836.
   PubMed Web of Science ®Google Scholar
• Shende P, Khanolkar B, Gaud RS. Drug repurposing: new strategies for addressing COVID-19 outbreak. Expert Rev Anti Infect Ther. 2021;19:689–706.
   PubMed Web of Science ®Google Scholar
• Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11:2251.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Biggioggero M, Maioli G, et al. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis. 2020;20(9):1012–1013.
   PubMed Web of Science ®Google Scholar
• Sultana J, Crisafulli S, Gabbay F, et al. Challenges for drug repurposing in the COVID-19 pandemic era. Front Pharmacol. 2020;11:588654.
   PubMed Web of Science ®Google Scholar
• Parvathaneni V, Gupta V. Utilizing drug repurposing against COVID-19 – efficacy, limitations, and challenges. Life Sci. 2020;259:118275.
   PubMed Web of Science ®Google Scholar
• Clout AE, Della Pasqua O, Hanna MG, et al. Drug repurposing in neurological diseases: an integrated approach to reduce trial and error. J Neurol Neurosurg Psychiatry. 2019;90:1270–1275.
   PubMed Web of Science ®Google Scholar
• Lyapustina S. Regulatory pitfalls and opportunities when repurposing for inhalation therapy. Adv Drug Deliv Rev. 2018;133:57–65.
   PubMed Web of Science ®Google Scholar
• Newman SP. Delivering drugs to the lungs: the history of repurposing in the treatment of respiratory diseases. Adv Drug Deliv Rev. 2018;133:5–18.
   PubMed Web of Science ®Google Scholar
• Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv; 2020.
   Google Scholar
• Zhou Y, Hou Y, Shen J, et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6:14.
   PubMed Web of Science ®Google Scholar
• Shah B, Modi P, Sagar SR. In silico studies on therapeutic agents for COVID-19: drug repurposing approach. Life Sci. 2020;252:117652.
   PubMed Web of Science ®Google Scholar
• Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248:117477.
   PubMed Web of Science ®Google Scholar
• Hall DC, Ji H-F. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis. 2020;35:101646.
   Google Scholar
• Kandeel M, Al-Nazawi M. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. Life Sci. 2020;251:117627.
   PubMed Web of Science ®Google Scholar
• Hall DC, Ji H-F. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis. 2020;35:101646.
   PubMed Web of Science ®Google Scholar